CN113293129B - 一种促进成骨前体细胞增殖的功能肽混合粉及其应用 - Google Patents
一种促进成骨前体细胞增殖的功能肽混合粉及其应用 Download PDFInfo
- Publication number
- CN113293129B CN113293129B CN202110335321.7A CN202110335321A CN113293129B CN 113293129 B CN113293129 B CN 113293129B CN 202110335321 A CN202110335321 A CN 202110335321A CN 113293129 B CN113293129 B CN 113293129B
- Authority
- CN
- China
- Prior art keywords
- functional peptide
- mixed powder
- functional
- peptide
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 222
- 239000011812 mixed powder Substances 0.000 title claims abstract description 59
- 230000002188 osteogenic effect Effects 0.000 title claims abstract description 30
- 239000002243 precursor Substances 0.000 title claims abstract description 29
- 230000001737 promoting effect Effects 0.000 title claims abstract description 23
- 230000035755 proliferation Effects 0.000 title claims description 25
- 239000003094 microcapsule Substances 0.000 claims abstract description 101
- 239000000843 powder Substances 0.000 claims abstract description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 18
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 18
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 13
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 13
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 13
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 13
- 239000005018 casein Substances 0.000 claims abstract description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000021240 caseins Nutrition 0.000 claims abstract description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 13
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 13
- 239000011718 vitamin C Substances 0.000 claims abstract description 13
- 235000021119 whey protein Nutrition 0.000 claims abstract description 13
- 239000002356 single layer Substances 0.000 claims description 44
- 239000000463 material Substances 0.000 claims description 41
- 239000000835 fiber Substances 0.000 claims description 38
- 108010022355 Fibroins Proteins 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 25
- 238000001694 spray drying Methods 0.000 claims description 24
- 229920002472 Starch Polymers 0.000 claims description 23
- 239000008107 starch Substances 0.000 claims description 23
- 235000019698 starch Nutrition 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000012975 dibutyltin dilaurate Substances 0.000 claims description 17
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 14
- 108010035532 Collagen Proteins 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229920002301 cellulose acetate Polymers 0.000 claims description 12
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 11
- 229920002907 Guar gum Polymers 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 239000000665 guar gum Substances 0.000 claims description 9
- 235000010417 guar gum Nutrition 0.000 claims description 9
- 229960002154 guar gum Drugs 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 239000005711 Benzoic acid Substances 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 229920000875 Dissolving pulp Polymers 0.000 claims description 8
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 8
- 235000019502 Orange oil Nutrition 0.000 claims description 8
- 235000010233 benzoic acid Nutrition 0.000 claims description 8
- 150000001746 carotenes Chemical class 0.000 claims description 8
- 235000005473 carotenes Nutrition 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 235000021552 granulated sugar Nutrition 0.000 claims description 8
- 239000010502 orange oil Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 239000001509 sodium citrate Substances 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- 235000011083 sodium citrates Nutrition 0.000 claims description 8
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 15
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 239000002699 waste material Substances 0.000 abstract description 4
- 230000000050 nutritive effect Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000011241 protective layer Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 210000000963 osteoblast Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000010410 layer Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 208000001132 Osteoporosis Diseases 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000004945 emulsification Methods 0.000 description 7
- 238000000265 homogenisation Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/27—Xanthan not combined with other microbial gums
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明涉及鱼骨提取肽技术领域,针对现有技术的提取肽促进成骨前体细胞增殖能力差的问题,公开了一种促进成骨前体细胞增殖的功能肽混合粉及其应用,所述功能肽混合粉的配方包括:30~40%功能肽微胶囊;10~20%低聚半乳糖;5~10%酪蛋白磷酸肽;5~10%牛磺酸;5~10%维生素C;1~2%微晶纤维素和1~2%羧甲基纤维素;其余为乳清蛋白粉。通过在金枪鱼骨中提取的功能肽表面包覆保护层,通过控制功能肽的释放位置及释放速度,来提升功能肽的稳定性及其营养价值,促进人体肠道的吸收,制备出易于消化并能够充分吸收的功能肽制品,避免了功能肽的浪费,降低功能肽制备成本。
Description
技术领域
本发明涉及鱼骨提取肽技术领域,尤其是涉及一种促进成骨前体细胞增殖的功能肽混合粉及其应用。
背景技术
骨质疏松症是由于多种原因导致的骨密度和骨质量下降,骨微结构破坏,造成骨脆性增加,从而容易发生骨折的全身性骨病。随着社会老龄化加剧,骨质疏松症的发病率已跃居世界各种常见疾病的第7位,被公认为严重的社会公共健康问题。骨质疏松的发病与生活习惯、激素调控及遗传多种因素有关,是多因素共同作用的结果。目前研究学者大都从引起骨吸收和骨形成平衡被打破的因素找起。成骨细胞主要参与骨形成,破骨细胞参与骨吸收,从细胞生物学角度讲,骨平衡就是成骨细胞和破骨细胞在骨成熟过程中的相互制约关系。成骨细胞作为骨形成过程中的最关键的功能细胞,其所分泌的骨基质,在骨重建的过程中是必不可少的,并且成骨细胞的增殖也可以生成丰富的胶原,通过基质钙化的方式生成更多的新的骨组织。此外若成骨细胞的数目减少,生物功能降低,将会导致骨形成的减少,骨密度的降低,骨小梁逐渐变窄,又因为成骨细胞聚集至骨陷窝处的能力减弱,被破骨细胞吸收的骨陷窝无法得到修补,最终导致骨的减少。所以骨质疏松发生的一个很重要的原因是成骨细胞的数量与功能相对不足。
目前,传统骨质疏松症治疗药物主要包括骨吸收抑制剂和骨形成促进剂。骨吸收抑制剂主要是通过抑制破骨细胞的形成和活性,从而抑制骨的吸收来减缓骨钙的丢失,但由于骨质疏松症患者通常都会钙吸收不足,若单独应用此类药物则可能造成低钙血症。而骨形成促进剂目前研究较少,主要包括甲状旁腺激素、细胞因子、氟化物和锶制剂等,但其来源有限,靶向性差也限制了其应用。随着现代患者在饮食与健康方面的意识提高,食源性生物活性肽因其具有安全、无毒副作用、价格竞争力强和易于吸收等优点在预防和治疗治骨质疏松领域受到了越来越广泛的关注。骨胶原蛋白占到骨组织有机质的90%以上,对于维持骨结构的完整性非常重要,并能够螯合钙质,防止骨组织钙质流失。骨胶原蛋白肽是骨胶原蛋白降解产生的多肽,研究表明,摄入胶原蛋白肽可以有效补充人体流失的胶原蛋白,这可能是因为部分低于10个氨基酸的短肽可以被肠道上皮细胞直接吸收,在体内合成蛋白质。因此,摄入骨胶原蛋白肽可以在人体内转化为骨胶原蛋白,从而达到防治骨组织钙质流失和骨质疏松症的效果。
专利号CN201910225417.0,专利名称“一种金枪鱼骨胶原多肽的制备方法”,本发明公开了一种金枪鱼骨胶原多肽的制备方法,包括如下步骤:将金枪鱼骨蛋白与蒸馏水混匀,并进行加热加压处理,得到金枪鱼骨蛋白浆液;调节金枪鱼骨蛋白浆液pH,并加入木瓜蛋白酶进行酶解,得到酶解液;将酶解液灭酶,得到灭酶酶解液;将灭酶酶解液静置冷却,离心取上清液后再进行超滤处理,得胶原多肽粗液;将胶原多肽粗液依次加入到阴离子交换树脂层析柱中洗脱,葡聚糖凝胶柱层析中洗脱,采用高效液相色谱进行纯化处理,即得金枪鱼骨胶原多肽。
其不足之处在于,骨胶原多肽后续服用过程中的容易被过早分解,稳定性难以保证,营养价值较低。
发明内容
本发明是为了克服现有提取肽促进成骨前体细胞增殖能力差的问题,提供一种促进成骨前体细胞增殖的功能肽混合粉及其应用,通过在金枪鱼骨中提取的功能肽表面包覆保护层,控制功能肽的释放位置及释放速度,来提升功能肽的稳定性及其营养价值,促进人体肠道的吸收,制备出易于消化并能够充分吸收的功能肽制品,避免了功能肽的浪费。
为了实现上述目的,本发明采用以下技术方案:
一种促进成骨前体细胞增殖的功能肽混合粉,所述功能肽混合粉的配方包括:30~40%功能肽微胶囊;10~20%低聚半乳糖;5~10%酪蛋白磷酸肽;5~10%牛磺酸;5~10%维生素C;1~2%微晶纤维素和1~2%羧甲基纤维素;其余为乳清蛋白粉。
上述各组分的添加既能增加功能肽混合粉的口感,又能提升功能肽混合粉的营养组分,使得功能肽混合粉整体的营养价值更高,各添加组分之间的融合性能较好,不会相互发生反应,破坏彼此的营养成分有效性。另外,功能肽微胶囊的壁材含有瓜尔豆胶和黄原胶,在水中溶解后会以胶体溶液形式存在,添加一定量的微晶纤维素和羧甲基纤维素,可以提高功能肽混合粉溶液的稳定性,避免功能肽微胶囊在溶液中聚集成大颗粒而沉淀而影响其消化吸收。
作为优选,所述功能肽混合粉的配方包括:32~38%功能肽微胶囊;12~18%低聚半乳糖;7~9%酪蛋白磷酸肽;6~9%牛磺酸;7~9%维生素C;1.2~1.8%微晶纤维素和1.2~1.8%羧甲基纤维素;其余为乳清蛋白粉。
作为优选,所述功能肽混合粉的配方包括:35%功能肽微胶囊;15%低聚半乳糖;8%酪蛋白磷酸肽;8%牛磺酸;8%维生素C;1.5%微晶纤维素和1.5%羧甲基纤维素;其余为乳清蛋白粉。
作为优选,所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至50-55℃反应,反应完毕后加入功能肽粉,并继续搅拌20-25min,2000-2300r/min条件下均质5-10min;所得溶液在进风温度45-50℃、出风温度30-35℃、进料速度70-90mL/h下进行喷雾干燥,制得单层包覆微胶囊;
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊。
本发明的功能肽微胶囊通过内部单层与壁材共同包覆来实现其在肠道中才会分解,且其内部的功能肽缓慢释放及均匀释放,有利于促进肠道的均匀吸收,且不会一次释放过多功能肽导致肠道来不及吸收而造成浪费。壁材成分保证功能肽的口感及其在口腔、食管及胃中的稳定性,防止功能肽过早的释放,而在未达到肠道中时便发生水解,破坏功能肽的稳定性,影响其营养成分及其吸收后的功能作用。
步骤(1)中单层包覆微胶囊中单层壳层的作用主要是对包覆的功能肽粉起到缓释且均匀释放的作用,因为单层包覆微胶囊壳层中含有淀粉及蚕丝蛋白纤维,而肠道中含有淀粉酶与胰蛋白酶,当功能肽微胶囊到达肠道中后,在碱性环境中壁材降解,将单层包覆微胶囊裸露出来。单层包覆微胶囊在肠液的作用下,由于淀粉具有较强的亲水性,蚕丝蛋白纤维的亲水性要差,所以淀粉会更快受到淀粉酶的酶解作用,促进淀粉酶的水解,当淀粉被水解后,单层壳层产生小孔,内部的功能肽会开始释放;当功能肽微胶囊中的部分功能肽释放之后,肠液会通过小孔进入到功能肽微胶囊内部,单层包覆微胶囊的单层壳层会受到胰蛋白酶的内外渗透并酶解,蚕丝蛋白纤维被酶解消化之后会形成不连续的残段纤维,由于蚕丝蛋白纤维占单层壳层的比重较大,当其被部分酶解消化之后,单层壳层结构会逐步具有更多的孔隙甚至包覆结构坍塌,对内部剩余的功能肽起到释放或者挤压作用,促进剩余功能肽的释放。该结构变化避免了随着功能肽逐步释放所带来的功能肽微胶囊内部后续剩余肽无法快速释放或者充分释放的问题,使得功能肽微胶囊中功能肽充分释放并且是均匀释放,促进了肠道均匀吸收,避免了功能肽的浪费。
单层壳层具体反应机理为:本发明采用含有多羧基与羟基的醋酸纤维素作为包覆层主体,再加入二聚丙三醇,二者在二月桂酸二丁基锡催化作用下发生酯化反应,进一步发生聚合反应,形成单层包覆微胶囊的壳层,二者在酯化反应与聚合反应的过程中,所形成酯化产物与聚合产物同时与蚕丝蛋白纤维表面的氨基及淀粉表面的羟基进行反应,使各成分之间产生连接的化学键,最终醋酸纤维素聚合产物与蚕丝蛋白纤维、淀粉形成一个整体性好且包覆性能好、流动性高,均匀性好的包覆壳层。
作为优选,步骤(1)中,醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为20-22g:450-480mL:15-18g:40-45mL:12-16g:0.5-0.8g:15-20g。
作为优选,步骤(1)中,所述蚕丝蛋白纤维的长度为1-1.5mm
作为优选,步骤(2)中,单层包覆微胶囊与壁材的质量比为5:1~10:1;乳化均质条件:温度50~60℃,转速1500~1800rpm;喷雾干燥的条件:进风温度40~50℃,出风温度30~35℃,进料速度35~40mL/min。
作为优选,步骤(2)中,壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=160~165g:182~185g:300~310g:182~185g:57~60g:380~390g:36~40g:30~35g:50~60g。
本发明所使用的壁材与单层包覆微胶囊之间具有较好的相容性,同时壁材成分也与功能肽混合粉的组分微晶纤维素和羧甲基纤维素相互作用形成稳定的胶体溶液,对功能肽微胶囊起到多重保护作用。
所述的促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。
作为优选,所述饮品的制备过程:在40~55℃的温水中加入质量分数2~5%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
采用冲泡方式进行服用,能够随取随饮,功能肽混合粉在温水中,具有较好的溶解性与稳定性,且不会破坏功能肽微胶囊的结构,使得服用更加方便。
因此,本发明具有如下有益效果:
(1)提供一种促进成骨前体细胞增殖的功能肽混合粉及其应用,通过在金枪鱼骨中提取的功能肽表面包覆保护层,通过控制功能肽的释放位置及释放速度;
(2)通过双层材料的包覆,来保证功能肽在肠道中释放,保护功能肽结构不被破坏,同时保证功能肽的释放速度达到匀速,最大限度的保证功能肽能够被及时吸收;
(3)提升功能肽的稳定性及其营养价值,促进人体肠道的吸收,制备出易于消化并能够充分吸收的功能肽制品,避免了功能肽的浪费,降低功能肽制备成本。
具体实施方式
下面结合具体实施方式对本发明做进一步的描述。
总实施例
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在40~55℃的温水中加入质量分数2~5%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:30~40%功能肽微胶囊;10~20%低聚半乳糖;5~10%酪蛋白磷酸肽;5~10%牛磺酸;5~10%维生素C;1~2%微晶纤维素和1~2%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至50-55℃反应,反应完毕后加入功能肽粉,并继续搅拌20-25min,2000-2300r/min条件下均质5-10min;所得溶液在进风温度45-50℃、出风温度30-35℃、进料速度70-90mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为20-22g:450-480mL:15-18g:40-45mL:12-16g:0.5-0.8g:15-20g;所述蚕丝蛋白纤维的长度为1-1.5mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=160~165g:182~185g:300~310g:182~185g:57~60g:380~390g:36~40g:30~35g:50~60g;单层包覆微胶囊与壁材的质量比为5:1~10:1;乳化均质条件:温度50~60℃,转速1500~1800rpm;喷雾干燥的条件:进风温度40~50℃,出风温度30~35℃,进料速度35~40mL/min。
实施例1
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在48℃的温水中加入质量分数3.5%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:35%功能肽微胶囊;15%低聚半乳糖;8%酪蛋白磷酸肽;8%牛磺酸;8%维生素C;1.5%微晶纤维素和1.5%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至53℃反应,反应完毕后加入功能肽粉,并继续搅拌22min,2150r/min条件下均质8min;所得溶液在进风温度48℃、出风温度33℃、进料速度80mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为21g:465mL:16.5g:42mL:14g:0.65g:18g;所述蚕丝蛋白纤维的长度为1.2mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=162g:183.5g:305g:182~185g:58g:385g:38g:33g:55g;单层包覆微胶囊与壁材的质量比为7:1;乳化均质条件:温度55℃,转速1650rpm;喷雾干燥的条件:进风温度45℃,出风温度32℃,进料速度38mL/min。
实施例2
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在40℃的温水中加入质量分数2%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:30%功能肽微胶囊;20%低聚半乳糖;5%酪蛋白磷酸肽;10%牛磺酸;5%维生素C;2%微晶纤维素和1%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至50℃反应,反应完毕后加入功能肽粉,并继续搅拌25min,2000r/min条件下均质10min;所得溶液在进风温度45℃、出风温度35℃、进料速度70mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为20g:450mL:15g:45mL:12g:0.8g:15g;所述蚕丝蛋白纤维的长度为1.5mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=160g:185g:300g:182g:60g:380g:40g:30g:60g;单层包覆微胶囊与壁材的质量比为8:1;乳化均质条件:温度50℃,转速1500rpm;喷雾干燥的条件:进风温度50℃,出风温度30℃,进料速度40mL/min。
实施例3
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在55℃的温水中加入质量分数2%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:40%功能肽微胶囊;10%低聚半乳糖;5%酪蛋白磷酸肽;10%牛磺酸;5%维生素C;1%微晶纤维素和2%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至50℃反应,反应完毕后加入功能肽粉,并继续搅拌25min,2000r/min条件下均质5min;所得溶液在进风温度50℃、出风温度30℃、进料速度70mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为20g:480mL:15g:45mL:12g:0.8g:15g;所述蚕丝蛋白纤维的长度为1mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=160g:182g:310g:182g:60g:380g:40g:30g:60g;单层包覆微胶囊与壁材的质量比为5:1;乳化均质条件:温度50℃,转速1800rpm;喷雾干燥的条件:进风温度40℃,出风温度35℃,进料速度35mL/min。
实施例4
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在43℃的温水中加入质量分数3%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:32%功能肽微胶囊;12%低聚半乳糖;6%酪蛋白磷酸肽;6%牛磺酸;9%维生素C;1.2%微晶纤维素和1.8%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至51℃反应,反应完毕后加入功能肽粉,并继续搅拌21min,2100r/min条件下均质6min;所得溶液在进风温度46℃、出风温度31℃、进料速度75mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为21.5g:470mL:17g:44mL:15g:0.7g:19g;所述蚕丝蛋白纤维的长度为1.4mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=161g:183g:302g:184g:59g:382g:37g:32g:52g;单层包覆微胶囊与壁材的质量比为6:1;乳化均质条件:温度52℃,转速1600rpm;喷雾干燥的条件:进风温度42℃,出风温度31℃,进料速度39mL/min。
实施例5
1、促进成骨前体细胞增殖的功能肽混合粉在饮品中的应用。所述饮品的制备过程:在53℃的温水中加入质量分数4%的功能肽混合粉,搅拌均匀使其完全溶解,得到功能肽饮品。
2、所述功能肽混合粉的配方包括:38%功能肽微胶囊;18%低聚半乳糖;8%酪蛋白磷酸肽;6%牛磺酸;8%维生素C;1.8%微晶纤维素和1.8%羧甲基纤维素;其余为乳清蛋白粉。
3、所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至54℃反应,反应完毕后加入功能肽粉,并继续搅拌24min,2250r/min条件下均质8min;所得溶液在进风温度49℃、出风温度34℃、进料速度85mL/h下进行喷雾干燥,制得单层包覆微胶囊;醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为21.5g:455mL:16g:42mL:13g:0.6g:17g;所述蚕丝蛋白纤维的长度为1.1mm。
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=164g:184g:308g:184g:58g:388g:37g:33g:58g;单层包覆微胶囊与壁材的质量比为9:1;乳化均质条件:温度58℃,转速1750rpm;喷雾干燥的条件:进风温度48℃,出风温度34℃,进料速度39mL/min。
对比例1与实施例1的区别在于,功能肽未进行包覆,其余步骤均与实施例1相同。
对比例2与实施例1的区别在于,功能肽微胶囊未包覆壁材,其余步骤均与实施例1相同。
对比例3与实施例1的区别在于,功能肽微胶囊未进行内层包覆,即未包覆单层壳层,其余步骤均与实施例1相同。
对比例4与实施例1的区别在于,单层包覆微胶囊之比过程中未加入蚕丝蛋白纤维,其余步骤均与实施例1相同。
对比例5与实施例1的区别在于,蚕丝蛋白纤维的加入量过量,由14g增加到了25g,其余步骤均与实施例1相同。
对比例6与实施例1的区别在于,单层包覆微胶囊与壁材的质量比过大为15:1,其余步骤均与实施例1相同。
对比例7与实施例1的区别在于,功能肽混合粉中未加入微晶纤维素和羧甲基纤维素,其余步骤均与实施例1相同。
对以上实施例及对比例,通过检测成骨功能肽微胶囊在模拟胃液环境和模拟小肠液环境中的释放速度,评估微胶囊对成骨功能肽在胃液环境下的保护效果以及在肠道环境的缓释效果。
(1)在模拟胃液环境中的释放精确称取已干燥的微囊100mg装入100mL锥形瓶,加入新鲜配制的人工胃液50mL,恒温水浴振荡器中(37±1)℃、60r/min条件下反应,每隔1h取出3mL模拟胃液,在280nm波长处测定吸光度,同时补充同体积模拟胃液。根据标准曲线计算模拟胃液中肽含量,计算肽的释放率。
释放率(%)=胃液模拟液中释放的总肽量/(加入的微囊质量×载药质量)×100(2)在模拟小肠液环境中的释放将100mg微囊加入50mL模拟肠液中,测定方法与在模拟胃液中相同。
表1成骨功能肽微胶囊在胃蛋白酶和淀粉酶作用下的保持率结果
对以上实施例及对比例,通过检测成骨功能肽混合粉对成骨前体细胞增殖率和分化的影响,进行评估其应用效果。
(1)成骨前体细胞增殖率检测
从液氮中取出冻存架,取成骨前体细胞MC3T3-E进行复苏培养传代1-2次后,取正常生长的成骨前体细胞MC3T3-E1,以每孔5×103/100μL/孔接种到96孔板,培养1天后,换液含加功能肽混合粉终浓度至500mg/L的培养液培养,设不含功能肽的培养液为对照组,每组设5个重复孔,培养2天后加5mg/mL的MTT20μL/孔,培养4h后去除上清,每孔加100μL DMSO震荡10min,570nm酶标仪检测吸光度OD值。
增殖率=(OD样品-OD对照)×100%/OD对照
(2)成骨前体细胞的分化检测
碱性磷酸酶(ALP)是成骨细胞分泌的一种功能性酶,组织与细胞表达的特异性强,ALP通过分解磷酸酯使局部的无机磷浓度增加,以促进基质的矿化,ALP的活力与骨的形成密切相关,因此是检测成骨细胞的存在和成骨细胞分化成熟的特异性标志。
按照上述方案进行培养,以每孔5×103/100μL/孔接种到96孔板,培养1天后,换液含加功能肽粉混合粉终浓度至500mg/L培养液培养,设不含功能肽粉培养液为对照组,每组设5个重复孔,隔天换液,培养5天后弃培养液,用PBS洗两次,加入0.2%的TritonX-100 50μL4℃过夜裂解细胞,取裂解液上清根据碱性磷酸酶(ALP)检测试剂盒说明书操作,检测碱性磷酸酶(ALP)的活力。
表1各项目制备得到促进成骨前体细胞增殖功能肽对成骨前体细胞增殖率影响
项目 | MC3T3-E1成骨细胞增殖率 | MC3T3-E1成骨细胞ALP活性 |
实施例1 | 24.3% | 0.85U/mg prot |
实施例2 | 26.0% | 0.87U/mg prot |
实施例3 | 25.6% | 0.88U/mg prot |
实施例4 | 24.9% | 0.86U/mg prot |
实施例5 | 25.4% | 0.85U/mg prot |
对比例1 | 19.2% | 0.73U/mg prot |
对比例2 | 17.7% | 0.72U/mg prot |
对比例3 | 15.8% | 0.71U/mg prot |
对比例4 | 16.5% | 0.69U/mg prot |
对比例5 | 16.9% | 0.71U/mg prot |
对比例6 | 17.3% | 0.73U/mg prot |
对比例7 | 13.9% | 0.61U/mg prot |
结论:经过评估后的结果可以看出,由实施例1-5可以看出,在本发明制备步骤及制备工艺范围内制备出来的功能肽具有较高的促MC3T3-E1成骨细胞增殖率,并且促进MC3T3-E1成骨细胞的分化,具有较强的稳定性与促吸性,保质期限更长,保证功能肽在肠道中释放,保护功能肽结构不被破坏,同时保证功能肽的释放速度达到匀速,最大限度的保证功能肽能够被及时吸收,大大提升功能肽混合粉的营养价值。
对比例1与实施例1的区别在于,功能肽未进行包覆;未进行包覆的功能肽稳定性较差,当其从口腔经食管到达胃部的时候,均会发生水解,当其到达肠道吸收部位的时候,功能肽的结构大部分以遭到破坏,所以其性能评估较差。
对比例2与实施例1的区别在于,功能肽微胶囊未包覆壁材;本发明的壁材是能够起到防止功能肽微胶囊在到达肠道之前发生水解的作用,若未包覆壁材,则单层微胶囊在胃部便会发生酶解释放,功能肽会遭到破坏,致使其最终的功能性下降。
对比例3与实施例1的区别在于,功能肽微胶囊未进行内层包覆,即未包覆单层壳层;当功能肽微胶囊到达肠道之后,在碱性肠液的作用下功能肽微胶囊内部的功能肽会瞬间释放,使得肠道来不及充分吸收,多余的功能肽便提早释放遭到破坏或者前往下一站,造成功能肽浪费,同时也缩短了肠道吸收周期。
对比例4与实施例1的区别在于,单层包覆微胶囊之比过程中未加入蚕丝蛋白纤维;未加入蚕丝蛋白纤维,当淀粉被水解后内部的功能肽被释放出来,但是随着功能肽的逐步释放,功能肽微胶囊内的功能肽便会减少,在相同孔径释放通路的条件下,会使得其释放浓度降低,后续功能肽释放过慢甚至来不及完全释放便随着微胶囊壳体一起排出体外,降低功能肽混合粉的营养价值。
对比例5与实施例1的区别在于,功能肽微胶囊中蚕丝蛋白纤维的加入量过量,由14g增加到了25g;由于内层单层壳层中蚕丝蛋白纤维的加入量过多,就使得内层单层壳层在胰蛋白酶的酶解作用下过多的破坏并过早的坍塌,使得最终功能肽过多过早的释放,造成与对比例3类似的影响。
对比例6与实施例1的区别在于,单层包覆微胶囊与壁材的质量比过大为15:1;壁材成分过少,会使得其对功能肽微胶囊整体的保护性能较差,最终对功能肽微胶囊的包覆结构造成过早的破坏,进而破坏功能肽分子结构,降低其营养价值。
对比例7与实施例1的区别在于,功能肽混合粉中未加入微晶纤维素和羧甲基纤维素;未添加微晶纤维素和羧甲基纤维素会使得功能肽混合粉在水中稳定性降低,导致功能肽微胶囊聚集成大的颗粒而沉淀,影响功能肽的消化吸收。
由上述实施例1~5及对比例1~7相关的数据可知,只有在本发明权利要求范围内的方案,才能够在各方面均能满足上述要求,得出最优化的方案,得到最优的功能肽混合粉。而对于配比的改动、原料的替换/加减,或者加料顺序的改变,均会带来相应的负面影响。
本发明中所用原料、设备,若无特别说明,均为本领域的常用原料、设备;本发明中所用方法,若无特别说明,均为本领域的常规方法。
以上所述,仅是本发明的较佳实施例,并非对本发明作任何限制,凡是根据本发明技术实质对以上实施例所作的任何简单修改、变更以及等效变换,均仍属于本发明技术方案的保护范围。
Claims (5)
1.一种促进成骨前体细胞增殖的功能肽混合粉,其特征在于,所述功能肽混合粉的配方包括:30~40%功能肽微胶囊;10~20%低聚半乳糖;5~10%酪蛋白磷酸肽;5~10%牛磺酸;5~10%维生素C;1~2%微晶纤维素和1~2%羧甲基纤维素;其余为乳清蛋白粉;
所述功能肽微胶囊的制备过程为:
(1)将醋酸纤维素溶于乙醇中,加入淀粉混合均匀,滴加二聚丙三醇,继续加入蚕丝蛋白纤维和二月桂酸二丁基锡,升温至50-55℃反应,反应完毕后加入金枪鱼骨胶原多肽功能肽粉,并继续搅拌20-25min,2000-2300r/min条件下均质5-10 min;所得溶液在进风温度45-50℃、出风温度30-35℃、进料速度70-90mL/h下进行喷雾干燥,制得单层包覆微胶囊;
(2)将壁材各组分按照比例混匀,加入上述单层包覆微胶囊混匀采用均质机进行乳化均质处理,再进行喷雾干燥,得到功能肽微胶囊;
步骤(1)中,醋酸纤维素、乙醇、淀粉、二聚丙三醇、蚕丝蛋白纤维、二月桂酸二丁基锡及功能肽粉的比例为:20-22g:450-480mL:15-18g:40-45 mL:12-16g:0.5-0.8g:15-20g;
步骤(2)中,单层包覆微胶囊与壁材的质量比为5:1 ~10:1;壁材组分及质量比:瓜尔豆胶、黄原胶、白糊精、桔子油香精、胡萝卜素、柠檬酸钠、苯甲酸、白砂糖及水=160~165g:182~185g:300~310g:182~185g:57~60g:380~390g:36~40g:30~35g:50~60g。
2.根据权利要求1所述的一种促进成骨前体细胞增殖的功能肽混合粉,其特征在于,所述功能肽混合粉的配方包括:32~38%功能肽微胶囊;12~18%低聚半乳糖;7~9%酪蛋白磷酸肽;6~9%牛磺酸;7~9%维生素C;1.2~1.8%微晶纤维素和1.2~1.8%羧甲基纤维素;其余为乳清蛋白粉。
3.根据权利要求1所述的一种促进成骨前体细胞增殖的功能肽混合粉,其特征在于,所述功能肽混合粉的配方包括:35%功能肽微胶囊;15%低聚半乳糖;8%酪蛋白磷酸肽;8%牛磺酸;8%维生素C;1.5%微晶纤维素和1.5%羧甲基纤维素;其余为乳清蛋白粉。
4.根据权利要求1所述的一种促进成骨前体细胞增殖的功能肽混合粉,其特征在于,步骤(1)中,所述蚕丝蛋白纤维的长度为1-1.5mm。
5.根据权利要求1所述的一种促进成骨前体细胞增殖的功能肽混合粉,其特征在于,步骤(2)中,乳化均质条件:温度50~60℃,转速1500~1800 rpm;喷雾干燥的条件:进风温度40~50℃,出风温度30~35℃,进料速度35~40 mL/min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110335321.7A CN113293129B (zh) | 2021-03-29 | 2021-03-29 | 一种促进成骨前体细胞增殖的功能肽混合粉及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110335321.7A CN113293129B (zh) | 2021-03-29 | 2021-03-29 | 一种促进成骨前体细胞增殖的功能肽混合粉及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113293129A CN113293129A (zh) | 2021-08-24 |
CN113293129B true CN113293129B (zh) | 2022-06-17 |
Family
ID=77319282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110335321.7A Active CN113293129B (zh) | 2021-03-29 | 2021-03-29 | 一种促进成骨前体细胞增殖的功能肽混合粉及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113293129B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1110136A (zh) * | 1994-12-05 | 1995-10-18 | 上海第二医科大学附属仁济医院 | 一种肠溶性细菌酶复层微囊制剂及制备方法 |
US20080199516A1 (en) * | 2005-07-26 | 2008-08-21 | Glaxo Group Limited | Encapsulation Of Lipid-Based Formulations In Enteric Polymers |
CN104745665A (zh) * | 2015-04-20 | 2015-07-01 | 广西大学 | 具有促进骨骼生长作用的胶原肽及其制备方法和应用 |
CN108095074A (zh) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | 一种辅助治疗骨质疏松症的金枪鱼鱼骨保健食品及其制备方法 |
CN111132667A (zh) * | 2017-09-29 | 2020-05-08 | 强生消费者公司 | 固体西甲硅油颗粒及其剂型 |
-
2021
- 2021-03-29 CN CN202110335321.7A patent/CN113293129B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1110136A (zh) * | 1994-12-05 | 1995-10-18 | 上海第二医科大学附属仁济医院 | 一种肠溶性细菌酶复层微囊制剂及制备方法 |
US20080199516A1 (en) * | 2005-07-26 | 2008-08-21 | Glaxo Group Limited | Encapsulation Of Lipid-Based Formulations In Enteric Polymers |
CN104745665A (zh) * | 2015-04-20 | 2015-07-01 | 广西大学 | 具有促进骨骼生长作用的胶原肽及其制备方法和应用 |
CN111132667A (zh) * | 2017-09-29 | 2020-05-08 | 强生消费者公司 | 固体西甲硅油颗粒及其剂型 |
CN108095074A (zh) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | 一种辅助治疗骨质疏松症的金枪鱼鱼骨保健食品及其制备方法 |
Non-Patent Citations (3)
Title |
---|
Study of high amylose corn starch as food grade enteric coating in a microcapsule model system;Anna Dimantov等;《Innovative Food Science and Emerging Technologies》;20041231;第5卷;第93-100页 * |
微胶囊技术及其在食品添加剂工业中的应用概况;赵阳;《中国食品添加剂》;20091231;第182-187页 * |
金枪鱼骨胶原蛋白肽螯合钙制备工艺及对MG-63细胞碱性磷酸酶分泌的影响;杨会成等;《中国海洋药物》;20200228;第39卷(第1期);第9-18页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113293129A (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Intra-articular delivery of sinomenium encapsulated by chitosan microspheres and photo-crosslinked GelMA hydrogel ameliorates osteoarthritis by effectively regulating autophagy | |
CN102552546A (zh) | 茶多酚海藻酸钠微球及其制备方法和应用 | |
RU2386443C1 (ru) | Способ получения биологически активного концентрата из пантов | |
CN113293129B (zh) | 一种促进成骨前体细胞增殖的功能肽混合粉及其应用 | |
CN113072616B (zh) | 一种促进成骨前体细胞增殖的功能肽微胶囊及其制备方法 | |
CN110313618B (zh) | 一种维生素d2微胶囊的制备方法 | |
CN108576816A (zh) | 一种增加骨密度的组合物 | |
CN101130065A (zh) | 一种珍珠钙软胶囊及制备方法 | |
CN102670523A (zh) | 一种注射用还原型谷胱甘肽冻干粉制备方法 | |
CN111184870A (zh) | 一种耐胃液消化型虾青素递送体的制备方法 | |
CN109528685A (zh) | 一种葫芦巴皂苷肠溶微胶囊制剂及其制备方法 | |
CN114468272A (zh) | 一种基于新型反溶剂法的疏水外壳凝胶微粒的制备方法及应用 | |
CN109820880A (zh) | 一种改善胃肠功能和肿瘤放化疗反应的复方茯苓多糖颗粒 | |
CN109528684A (zh) | 一种mg53蛋白/mg53突变体蛋白肠溶胶囊及其制备方法 | |
CN113831420B (zh) | 肠溶海藻植物空心胶囊用超低粘度褐藻胶的制备及其应用 | |
JPH0220605B2 (zh) | ||
Ryszka et al. | Influence of prolactin and calcium gluconate concentration on permeation and intestinal absorption of Ca (II) ions | |
CN116491657B (zh) | 一种含有维生素d的钙制剂及其制备方法 | |
CN114230815B (zh) | 实现黄酮不同部位靶向释放的乳液凝胶珠及其制备方法 | |
CN111773180B (zh) | 一种甘露聚糖在诱导骨再生方面的应用 | |
CN113318093B (zh) | 一种含有维生素k2的补钙组合物及其制备方法与应用 | |
CN103232538B (zh) | 一种巯基化改性的胶原钙复合物 | |
Ostrovska et al. | STUDIES OF EFFICIENCY OF THE COMPOSITE SYSTEM “LYMPHOSILICA” IN MODELING EXPERIMENTAL OBESITY IN RATS | |
JPH05246846A (ja) | 蛋白質の消化促進組成物 | |
CN116444613A (zh) | 具有缓解非酒精性脂肪肝的多肽及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |